Subscribe to RSS
DOI: 10.1055/a-1801-2406
Detection of Barrett’s neoplasia with a near-infrared fluorescent heterodimeric peptide
Supported by: National Institutes of Health CA163059Trial Registration: ClinicalTrials.gov Registration number (trial ID): NCT03852576 Type of study: randomized
Abstract
Background Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease with poor prognosis that is rising rapidly in incidence. We aimed to demonstrate specific binding by a peptide heterodimer to Barrett’s neoplasia in human subjects.
Methods Peptide monomers specific for EGFR and ErbB2 were arranged in a heterodimer configuration and labeled with IRDye800. This near-infrared (NIR) contrast agent was topically administered to patients with Barrett’s esophagus (BE) undergoing either endoscopic therapy or surveillance. Fluorescence images were collected using a flexible fiber accessory passed through the instrument channel of an upper gastrointestinal endoscope. Fluorescence images were collected from 31 BE patients. A deep learning model was used to segment the target (T) and background (B) regions.
Results The mean target-to-background (T/B) ratio was significantly greater for high grade dysplasia (HGD) and EAC versus BE, low grade dysplasia (LGD), and squamous epithelium. At a T/B ratio of 1.5, sensitivity and specificity of 94.1 % and 92.6 %, respectively, were achieved for the detection of Barrett’s neoplasia with an area under the curve of 0.95. No adverse events attributed to the heterodimer were found. EGFR and ErbB2 expression were validated in the resected specimens.
Conclusions This “first-in-human” clinical study demonstrates the feasibility of detection of early Barrett’s neoplasia using a NIR-labeled peptide heterodimer.
Publication History
Received: 01 September 2021
Accepted after revision: 04 March 2022
Accepted Manuscript online:
17 March 2022
Article published online:
20 June 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA Cancer J Clin 2020; 70: 7-30
- 2 He H, Chen N, Hou Y. et al. Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis. Thorac Cancer 2020; 11: 1121-1128
- 3 Prasad GA, Bansal A, Sharma P. et al. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010; 105: 1490-1502
- 4 Sharma P, Savides TJ, Canto MI. et al. The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. Gastrointest Endosc 2012; 76: 252-254
- 5 Spechler SJ, Sharma P. American Gastroenterological Association. et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011; 140: 1084-1091
- 6 Sturm MB, Wang TD. Endoscopic imaging techniques: beyond narrow band. Am J Gastroenterol 2018; 113: 1103-1107
- 7 Cronin J, McAdam E, Danikas A. et al. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol 2011; 106: 46-56
- 8 Plum PS, Gebauer F, Krämer M. et al. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer 2019; 19: 38
- 9 Zhou J, Joshi BP, Duan X. et al. EGFR overexpressed in colonic neoplasia can be detected on wide-field endoscopic imaging. Clin Transl Gastroenterol 2015; 6: e101
- 10 Joshi BP, Zhou J, Pant A. et al. Design and synthesis of near-infrared peptide for in vivo molecular imaging of HER2. Bioconjug Chem 2016; 27: 481-494
- 11 Chen J, Zhou J, Gao Z. et al. Multiplexed targeting of Barrett’s neoplasia with a heterobivalent ligand: Imaging study on mouse xenograft in vivo and human specimens ex vivo. J Med Chem 2018; 61: 5323-5331
- 12 Chen J, Gao Z, Li G. et al. Dual-modal in vivo fluorescence and photoacoustic imaging using a heterodimeric peptide. Chem Comm 2018; 54: 13196-13199
- 13 Chen J, Jiang Y, Chang TS. et al. Multiplexed endoscopic imaging of Barrett's neoplasia using targeted fluorescent heptapeptides in a phase 1 proof-of-concept study. Gut 2021; 70: 1010-1013
- 14 Bird-Lieberman EL, Neves AA, Lao-Sirieix P. et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett’s esophagus. Nat Med 2012; 18: 315-321
- 15 Nagengast WB, Hartmans E, Garcia-Allende PB. et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut 2019; 68: 7-10
- 16 Labrijn AF, Janmaat ML, Reichert JM. et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 2019; 18: 585-608
- 17 Ding L, Tian C, Feng S. et al. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics 2015; 5: 378
- 18 Yan Y, Chen X. Peptide heterodimers for molecular imaging. Amino Acids 2011; 41: 1081-1092
- 19 Zhang J, Niu G, Lang L. et al. Clinical translation of a dual integrin αvβ3–and gastrin-releasing peptide receptor-targeting PET radiotracer, 68Ga-BBN-RGD. J Nucl Med 2017; 58: 228-234
- 20 Razumienko EJ, Chen JC, Cai Z. et al. Dual-receptor-targeted radioimmunotherapy of human breast cancer xenografts in athymic mice coexpressing HER2 and EGFR using 177Lu-or 111In-labeled bispecific radioimmunoconjugates. J Nucl Med 2016; 57: 444-452